Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Clin Ophthalmol ; 16: 1047-1053, 2022.
Article in English | MEDLINE | ID: mdl-35418742

ABSTRACT

Purpose: To evaluate how the HLA genotype is associated to the polypoidal choroidal vasculopathy (PCV) in a population of patients of Afro-Caribbean descent. Methods: Forty-seven patients were diagnosed with PCV. The number of control patients was 457. All affected patients and control patients were of Afro-Caribbean descent and natives to Martinique. HLA typing was based on blood sample, using the polymerase chain reaction technique. Comparison of HLA alleles between the 2 groups was done using chi-2 test, odds ratio (OR) and confidence interval using Woolf's method. The Bonferroni correction was considered significant when p-value ≤0.05. Alleles frequency was analyzed for DRB1 and DQB1 locus. Results: HLA-DRB1*13 allele was significantly associated to PCV (OR = 2.02, CI = [1.3; 3.13], p = 0.003). In group DRB1, the Bonferroni correction significance threshold was <0.004. HLA-DQB1*04 allele was significantly associated to PCV (OR = 3.5, CI = [1.48; 8.3], p = 0.006). In group DQB1, the Bonferroni correction significance threshold was <0.006. Conclusion: Two HLA alleles are positively associated to PCV. The possible association between PCV and certain alleles suggest HLA implication in PCV pathogeny, most likely by modeling the immune system response.

2.
PLoS Negl Trop Dis ; 12(3): e0006304, 2018 03.
Article in English | MEDLINE | ID: mdl-29554087

ABSTRACT

BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1) has been discovered in 1980 and has been linked to tropical spastic paraparesis (HAM/TSP) in 1985 in Martinique. There is no data on HAM/TSP incidence trends. We report, in the present work, the temporal trends incidence of HAM/TSP in Martinique over 25 years. METHODS: Martinique is a Caribbean French West Indies island deserved by a unique Neurology Department involved in HAM/TSP diagnosis and management. A registry has been set up since 1986 and patients diagnosed for a HAM/TSP were prospectively registered. Only patients with a definite HAM/TSP onset between 1986 and 2010 were included in the present study. The 25-year study time was stratified in five-year periods. Crude incidence rates with 95% confidence interval (95%CI) were calculated using Poisson distribution for each period. Age-standardized rates were calculated using the direct method and the Martinique population census of 1990 as reference. Standardized incidence rate ratios with 95% CIs and P trends were assessed from simple Poisson regression models. Number of HTLV-1 infection among first-time blood donors was retrospectively collected from the central computer data system of the Martinique blood bank. The HTLV-1 seroprevalence into this population has been calculated for four 5-year periods between 1996 and 2015. RESULTS: Overall, 153 patients were identified (mean age at onset, 53+/-13.1 years; female:male ratio, 4:1). Crude HAM/TSP incidence rates per 100,000 per 5 years (95%CI) in 1986-1990, 1991-1995, 1996-2000, 2001-2005 and 2006-2010 periods were 10.01 (6.78-13.28), 13.02 (9.34-16.70), 11.54 (8.13-14.95), 4.27 (2.24-6.28) and 2.03 (0.62-3.43). Age-standardized 5-year incidence rates significantly decreased by 69% and 87% in 2001-2005 and 2006-2010 study periods. Patients characteristics did not differ regarding 1986-2000 and 2001-2010 onset periods. Between 1996-2000 and 2011-2015 study periods, the HTLV-1 seroprevalence significantly decreased by 63%. CONCLUSION: Martinique faces a sudden and rapid decline of HAM/TSP incidence from 2001 in comparison to 1986-2000 periods. Reduction of HTLV-1 seroprevalence, that may result from transmission prevention strategy, could account for HAM/TSP incidence decrease.


Subject(s)
HTLV-I Antibodies/blood , HTLV-I Infections/epidemiology , Paraparesis, Tropical Spastic/epidemiology , Spinal Cord Diseases/epidemiology , Adult , Aged , Female , HTLV-I Infections/virology , Human T-lymphotropic virus 1/immunology , Human T-lymphotropic virus 1/isolation & purification , Humans , Incidence , Male , Martinique/epidemiology , Middle Aged , Paraparesis, Tropical Spastic/immunology , Paraparesis, Tropical Spastic/virology , Poisson Distribution , Public Health , Risk Factors , Seroepidemiologic Studies , Spinal Cord Diseases/immunology , Spinal Cord Diseases/virology , Time Factors
3.
Blood ; 118(24): 6306-9, 2011 Dec 08.
Article in English | MEDLINE | ID: mdl-21998206

ABSTRACT

HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a neurodegenerative disease of the central nervous system induced by human T-lymphotropic virus type 1. As a potential therapeutic approach, we previously suggested reducing the proviral load by modulating lysine deacetylase activity using valproic acid (VPA) and exposing virus-positive cells to the host immune response. We conducted a single-center, 2-year, open-label trial, with 19 HAM/TSP volunteers treated with oral VPA. Proviral load, CD38/HLA-DR expression, and CD8(+) lysis efficiency were not significantly affected by VPA. Mean scores of HAM/TSP disability did not differ between baseline and final visit. Walking Time Test increased significantly (> 20%) in 3 patients and was in keeping with minor VPA side effects (drowsiness and tremor). Walking Time Test improved rapidly after VPA discontinuation. We conclude that long-term treatment with VPA is safe in HAM/TSP.


Subject(s)
Enzyme Inhibitors/adverse effects , Paraparesis, Tropical Spastic/drug therapy , Paraparesis, Tropical Spastic/immunology , Valproic Acid/adverse effects , Adult , Aged , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/metabolism , Cytophagocytosis/drug effects , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/therapeutic use , Female , Human T-lymphotropic virus 1/drug effects , Humans , Immunity, Cellular/drug effects , Lymphocyte Activation/drug effects , Male , Middle Aged , Paraparesis, Tropical Spastic/blood , Paraparesis, Tropical Spastic/virology , Proviruses/drug effects , Severity of Illness Index , T-Lymphocytes, Cytotoxic/drug effects , T-Lymphocytes, Cytotoxic/immunology , Time Factors , Valproic Acid/administration & dosage , Valproic Acid/therapeutic use , Viral Load/drug effects
4.
Blood ; 118(9): 2483-91, 2011 Sep 01.
Article in English | MEDLINE | ID: mdl-21505188

ABSTRACT

A determinant of human T-lymphotropic virus-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) development is the HTLV-1-infected cell burden. Viral proteins Tax and HBZ, encoded by the sense and antisense strands of the pX region, respectively, play key roles in HTLV-1 persistence. Tax drives CD4(+)-T cell clonal expansion and is the immunodominant viral antigen recognized by the immune response. Valproate (2-n-propylpentanoic acid, VPA), a histone deacetylase inhibitor, was thought to trigger Tax expression, thereby exposing the latent HTLV-1 reservoir to immune destruction. We evaluated the impact of VPA on Tax, Gag, and HBZ expressions in cultured lymphocytes from HTLV-1 asymptomatic carriers and HAM/TSP patients. Approximately one-fifth of provirus-positive CD4(+) T cells spontaneously became Tax-positive, but this fraction rose to two-thirds of Tax-positive-infected cells when cultured with VPA. Valproate enhanced Gag-p19 release. Tax- and Gag-mRNA levels peaked spontaneously, before declining concomitantly to HBZ-mRNA increase. VPA enhanced and prolonged Tax-mRNA expression, whereas it blocked HBZ expression. Our findings suggest that, in addition to modulating Tax expression, another mechanism involving HBZ repression might determine the outcome of VPA treatment on HTLV-1-infected-cell proliferation and survival.


Subject(s)
Basic-Leucine Zipper Transcription Factors/biosynthesis , Gene Expression Regulation, Viral/drug effects , Gene Products, tax/biosynthesis , Human T-lymphotropic virus 1/physiology , Valproic Acid/pharmacology , Viral Proteins/biosynthesis , Antisense Elements (Genetics)/drug effects , Apoptosis/drug effects , Asymptomatic Diseases , Basic-Leucine Zipper Transcription Factors/genetics , Cells, Cultured/drug effects , Cells, Cultured/virology , Genes, gag , Genes, pX , Histone Acetyltransferases/antagonists & inhibitors , Humans , Lymphocytes/drug effects , Lymphocytes/virology , Paraparesis, Tropical Spastic , Proviruses/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , RNA, Viral/biosynthesis , RNA, Viral/genetics , Retroviridae Proteins , Viral Proteins/genetics , gag Gene Products, Human Immunodeficiency Virus/biosynthesis
5.
PLoS Pathog ; 6(11): e1001177, 2010 Nov 04.
Article in English | MEDLINE | ID: mdl-21079688

ABSTRACT

Human T cell leukemia virus type 1 (HTLV-1) is the etiologic agent of Adult T cell Leukemia (ATL) and the neurological disorder HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although the majority of HTLV-1-infected individuals remain asymptomatic carriers (AC) during their lifetime, 2-5% will develop either ATL or HAM/TSP, but never both. To better understand the gene expression changes in HTLV-1-associated diseases, we examined the mRNA profiles of CD4+ T cells isolated from 7 ATL, 12 HAM/TSP, 11 AC and 8 non-infected controls. Using genomic approaches followed by bioinformatic analysis, we identified gene expression pattern characteristic of HTLV-1 infected individuals and particular disease states. Of particular interest, the suppressor of cytokine signaling 1--SOCS1--was upregulated in HAM/TSP and AC patients but not in ATL. Moreover, SOCS1 was positively correlated with the expression of HTLV-1 mRNA in HAM/TSP patient samples. In primary PBMCs transfected with a HTLV-1 proviral clone and in HTLV-1-transformed MT-2 cells, HTLV-1 replication correlated with induction of SOCS1 and inhibition of IFN-α/ß and IFN-stimulated gene expression. Targeting SOCS1 with siRNA restored type I IFN production and reduced HTLV-1 replication in MT-2 cells. Conversely, exogenous expression of SOCS1 resulted in enhanced HTLV-1 mRNA synthesis. In addition to inhibiting signaling downstream of the IFN receptor, SOCS1 inhibited IFN-ß production by targeting IRF3 for ubiquitination and proteasomal degradation. These observations identify a novel SOCS1 driven mechanism of evasion of the type I IFN antiviral response against HTLV-1.


Subject(s)
Antiviral Agents/pharmacology , Biomarkers, Tumor/genetics , CD4-Positive T-Lymphocytes/physiology , Human T-lymphotropic virus 1/drug effects , Interferon Type I/pharmacology , Signal Transduction/drug effects , Suppressor of Cytokine Signaling Proteins/metabolism , Adult , Biomarkers, Tumor/metabolism , Blotting, Western , CD4-Positive T-Lymphocytes/drug effects , Case-Control Studies , Cells, Cultured , Gene Expression Profiling , HTLV-I Infections/genetics , HTLV-I Infections/metabolism , HTLV-I Infections/virology , Human T-lymphotropic virus 1/genetics , Humans , Immunoblotting , Immunoprecipitation , Oligonucleotide Array Sequence Analysis , Paraparesis, Tropical Spastic/genetics , Paraparesis, Tropical Spastic/metabolism , Paraparesis, Tropical Spastic/virology , RNA, Messenger/genetics , RNA, Small Interfering/genetics , RNA, Viral/genetics , Reverse Transcriptase Polymerase Chain Reaction , Suppressor of Cytokine Signaling 1 Protein , Suppressor of Cytokine Signaling Proteins/antagonists & inhibitors , Suppressor of Cytokine Signaling Proteins/genetics , Viral Load
6.
Int J Infect Dis ; 14(11): e986-90, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20851016

ABSTRACT

OBJECTIVES: Human T-cell lymphotropic virus type 1 (HTLV-1) infection leads to the risk of developing HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in less than 5% of cases. The mechanism of disease progression in HAM/TSP remains unknown. A significant role of certain human leukocyte antigen (HLA) genotypes in determining the risk of HAM/TSP has been reported in Japan, where the HLA-A*02 gene has been found to be associated with a lower HTLV-1 provirus load and with protection from HAM/TSP, whereas HLA-DRB1*0101 has been found to be associated with an increased susceptibility to HAM/TSP. The aim of the present case-control study was to investigate the HLA class I and class II allele distribution in HTLV-seropositive French Afro-Caribbean individuals, originating from the French West Indies. METHODS: Associations with HLA class I (A and B) and class II (DRB1 and DQB1) alleles were tested in 123 HAM/TSP patients and 85 asymptomatic HTLV-1 carriers. HLA typing was undertaken on genomic DNA extracted from peripheral blood leukocytes. RESULTS: In our cohort, no significant effect on either the risk of developing HAM/TSP or HTLV-1 provirus load was found for HLA class I or class II, including HLA-A*02 (p=0.43). CONCLUSIONS: Our findings are in contrast to those in the Japanese population, however the literature on HLA associations in HTLV-1 infections across different populations over the past decade have reported conflicting results and this suggests strong ethnic disparities.


Subject(s)
Alleles , Histocompatibility Antigens Class II/genetics , Histocompatibility Antigens Class I/genetics , Paraparesis, Tropical Spastic/genetics , Case-Control Studies , Ethnicity/genetics , Female , Follow-Up Studies , Genetic Predisposition to Disease , Human T-lymphotropic virus 1/immunology , Humans , Male , Martinique , Middle Aged , Paraparesis, Tropical Spastic/complications , Paraparesis, Tropical Spastic/ethnology , Proviruses/genetics , Proviruses/immunology , Risk Factors , Viral Load
7.
Front Biosci (Schol Ed) ; 1(1): 205-15, 2009 06 01.
Article in English | MEDLINE | ID: mdl-19482696

ABSTRACT

HTLV-1 (human T-lymphotropic virus type 1) and BLV (bovine leukemia virus) are two related retroviruses infecting CD4+ and B lymphocytes in humans and ruminants, respectively. During infection, the host-pathogen interplay is characterized by very dynamic kinetics resulting in equilibrium between the virus, which attempts to proliferate, and the immune response, which seeks to exert tight control of the virus. A major determinant of disease induction by both viruses is the accumulation of provirus in peripheral blood. In the absence of viral proteins, virus infected cells escape recognition and destruction by the host immune response. We propose a novel therapeutic strategy based on transient activation of viral expression using epigenetic modulators; this exposes infected cells to the immune response and results in significant reductions in proviral loads. In the absence of satisfactory therapies, this viral gene-activation strategy might delay progression, or even be curative, for HTLV-1 induced myelopathy / tropical spastic paraparesis (HAM/TSP).


Subject(s)
Gene Expression , Genetic Therapy , Leukemia Virus, Bovine/physiology , Models, Biological , Paraparesis, Tropical Spastic/therapy , Animals , Humans , Leukemia Virus, Bovine/genetics , Paraparesis, Tropical Spastic/genetics , Sheep
8.
Blood ; 110(10): 3722-8, 2007 Nov 15.
Article in English | MEDLINE | ID: mdl-17717136

ABSTRACT

Epigenetic modifications of chromatin may play a role in maintaining viral latency and thus persistence of the human T-lymphotropic virus type 1 (HTLV-1), which is responsible for HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP). A major determinant of disease progression is increased peripheral blood proviral load (PVL), possibly via the accumulation of infected cells in the central nervous system (CNS) creating a damaging inflammatory response. Current therapeutic approaches that focus on reducing either cell proliferation, viral replication, or tissue invasion are still unsatisfactory. Contrasting with these inhibitory strategies, we evaluated the efficacy of a novel approach aimed, paradoxically, at activating viral gene expression to expose virus-positive cells to the host immune response. We used valproate (VPA), a histone deacetylase inhibitor that has been used for decades as a chronic, safe treatment for epileptic disorders. Based on in vitro and in vivo data, we provide evidence that transient activation of the latent viral reservoir causes its collapse, a process that may alleviate the condition of HAM/TSP. This represents the first such approach to treating HAM/TSP, using gene activation therapy to tilt the host-pathogen balance in favor of an existing antiviral response. This trial is registered at http://clinicaltrials.gov/as no. NCT00519181.


Subject(s)
Histone Deacetylases/physiology , Human T-lymphotropic virus 1/growth & development , Paraparesis, Tropical Spastic/virology , Proviruses/growth & development , Transcriptional Activation/physiology , Viral Load , Enzyme Inhibitors/pharmacology , Gene Expression Regulation, Viral/drug effects , HeLa Cells , Histone Deacetylase Inhibitors , Humans , Jurkat Cells , Paraparesis, Tropical Spastic/genetics , Transfection , Valproic Acid/pharmacology
9.
Arch Neurol ; 63(11): 1560-6, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17101824

ABSTRACT

BACKGROUND: The progression of neurological disability in human T-lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) remains undefined. OBJECTIVES: To determine the time course of disability scores and to identify predictors of outcome among patients with HAM/TSP. DESIGN: Clinical 14-year follow-up study. SETTING: University hospital. Patients One hundred twenty-three patients with HAM/TSP. MAIN OUTCOME MEASURES: We determined time from onset to the following 4 Kurtzke Disability Status Scale (DSS) end points: scores of 6 (unilateral aid required), 6.5 (bilateral aid required), 8 (wheelchair confinement), and 10 (death related to the disease). Times to reach selected DSS scores were estimated using the Kaplan-Meier method. Univariate and multivariate analyses identified variables related to the rate of progression to DSS 8. The HTLV-1 proviral loads were also assessed. RESULTS: The disability of the cohort progressed throughout the follow-up period. The median times from onset to DSS 6, 6.5, and 8 were 6, 13, and 21 years, respectively. The median time from DSS 6 to DSS 8 was 8 years; DSS 10 was reached by one fourth of the patients within 20 years. Age at onset of 50 years or older and high HTLV-1 proviral load were associated with a shorter time to DSS 8 (P = .01 and P = .02, respectively). A shorter time to DSS 6 significantly adversely affected the time to progression from DSS 6 to DSS 8. CONCLUSIONS: Human T-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis is a rapidly disabling disease. Monitoring for HTLV-1 proviral load is recommended in future therapeutic trials.


Subject(s)
Human T-lymphotropic virus 1 , Paraparesis, Tropical Spastic/epidemiology , Paraparesis, Tropical Spastic/virology , Spinal Cord Diseases/epidemiology , Spinal Cord Diseases/virology , Age of Onset , Aged , Aged, 80 and over , Disability Evaluation , Disease Progression , Female , Follow-Up Studies , Humans , Male , Multivariate Analysis , Paraparesis, Tropical Spastic/diagnosis , Predictive Value of Tests , Retrospective Studies , Risk , Severity of Illness Index , Spinal Cord Diseases/diagnosis , Time Factors
10.
J Neurol Sci ; 237(1-2): 53-9, 2005 Oct 15.
Article in English | MEDLINE | ID: mdl-15972218

ABSTRACT

A high proviral load of human T cell lymphotropic virus type 1 (HTLV-1) in peripheral blood mononuclear cells (PBMCs) has been reported in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The aim of the present study was to investigate the role of HTLV-1 proviral load in PBMCs (expressed as the number of copies per 10(6) PBMCs) in HAM/TSP disease course. One hundred consecutive HAM/TSP patients were recruited and assigned on the basis of the disability score and disease duration to either a rapid (n=38) or a slow (n=62) progression group. Thirty-four asymptomatic HTLV-1 carriers were also included. HTLV-1 proviral load was quantified in all HAM/TSP patients and asymptomatic subjects. The mean HTLV-1 proviral load was 6-fold lower in asymptomatic carriers than in HAM/TSP patients (18,224+/-24,811 vs. 107,905+/-96,651, p<0.0001) and significantly higher in rapid progression patients than in slow progression patients (146,469+/-98,943 vs. 84,270+/-87,912, p=0.0002). HTLV-1 proviral load in HAM/TSP patients was independent of age at the time of study, age at onset, and disease duration, and was not related to ophthalmological-associated disease or Chisholm grade. A high level of pulmonary lymphocytosis correlated with high HTLV-1 proviral load level (p=0.01). Our results suggest that the level of HTLV-1 proviral load in PBMCs parallels the course of HTLV-1 infection, being low in asymptomatic carriers and high and very high, respectively, in slow and rapid progression HAM/TSP patients. The magnitude of the HTLV-1 proviral load in PBMCs can be used as a biological marker of disease progression and could be a useful marker of disease activity in the monitoring of therapeutic trials.


Subject(s)
Human T-lymphotropic virus 1 , Monocytes/virology , Paraparesis, Tropical Spastic/pathology , Paraparesis, Tropical Spastic/virology , Viral Load , Adult , Aged , Biomarkers , Cerebrospinal Fluid Proteins/chemistry , DNA, Viral/analysis , Disability Evaluation , Disease Progression , Eye/pathology , Eye/virology , Female , Humans , Immunoelectrophoresis , Immunoglobulin G/biosynthesis , Male , Middle Aged , Paraparesis, Tropical Spastic/cerebrospinal fluid
11.
J Infect Dis ; 191(11): 1830-4, 2005 Jun 01.
Article in English | MEDLINE | ID: mdl-15871115

ABSTRACT

Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is associated with accumulation of HTLV-I-infected T cells in the central nervous system (CNS). However, data on HTLV-I proviral load in the CNS at the asymptomatic stage are still lacking. We measured HTLV-I proviral load in cerebrospinal fluid (CSF) cells from 17 patients with HAM/TSP and 25 asymptomatic carriers. The percentage of HTLV-I-infected cells in CSF cells and the CSF cell : peripheral blood mononuclear cell HTLV-I proviral load ratio were always >10% and >1, respectively, in the patients with HAM/TSP but were always <10% and <1, respectively, in the asymptomatic carriers. We propose that determination of HTLV-I proviral load in CSF cells should be included as a new parameter for the diagnosis of HAM/TSP.


Subject(s)
Human T-lymphotropic virus 1/isolation & purification , Paraparesis, Tropical Spastic/cerebrospinal fluid , Paraparesis, Tropical Spastic/virology , Proviruses/isolation & purification , Viral Load , Adult , Aged , Antibodies, Viral/blood , Antibodies, Viral/cerebrospinal fluid , DNA, Viral/isolation & purification , Female , Humans , Leukocytes, Mononuclear/virology , Male , Middle Aged , Neopterin/cerebrospinal fluid
12.
Retrovirology ; 2: 4, 2005 Feb 01.
Article in English | MEDLINE | ID: mdl-15686595

ABSTRACT

BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1) proviral load is related to the development of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and has also been shown to be elevated in the peripheral blood in HTLV-1-infected patients with uveitis or alveolitis. Increased proliferation of HTLV-1-infected cells in, or migration of such cells into, the central nervous system is also seen in HAM/TSP. In the present study, we evaluated the proviral load in a cohort of HTLV-1-infected patients with arthritic conditions. RESULTS: HTLV-1 proviral load in the peripheral blood from 12 patients with RA and 6 patients with connective tissue disease was significantly higher than that in matched asymptomatic HTLV-1 carriers, but similar to that in matched HAM/TSP controls. HAM/TSP was seen in one-third of the HTLV-1-infected patients with RA or connective tissue disease, but did not account for the higher proviral load compared to the asymptomatic carrier group. The proviral load was increased in the synovial fluid and tissue from an HTLV-1-infected patient with RA, the values suggesting that the majority of infiltrated cells were HTLV-1-infected. In the peripheral blood from HTLV-1-infected patients with RA or connective tissue disease, HTLV-1 proviral load correlated with the percentages of memory CD4+ T cells and activated T cells, and these percentages were shown to be markedly higher in the synovial fluid than in the peripheral blood in an HTLV-1-infected patient with RA. CONCLUSIONS: These biological findings are consistent with a role of the retrovirus in the development of arthritis in HTLV-1-infected patients. A high level of HTLV-1-infected lymphocytes in the peripheral blood and their accumulation in situ might play a central role in the pathogenesis of HTLV-1-associated inflammatory disorders. Alternatively, the autoimmune arthritis, its etiological factors or treatments might secondarily enhance HTLV-1 proviral load.


Subject(s)
Arthritis, Rheumatoid/virology , Connective Tissue Diseases/virology , HTLV-I Infections/virology , Human T-lymphotropic virus 1/physiology , Proviruses/physiology , Viral Load , Adult , Aged , Arthritis, Rheumatoid/complications , Carrier State/virology , Connective Tissue Diseases/complications , DNA, Viral/blood , Female , HTLV-I Infections/complications , Humans , Male , Middle Aged , Paraparesis, Tropical Spastic/virology
13.
Transfusion ; 44(1): 42-8, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14692966

ABSTRACT

BACKGROUND: WBC depletion by filtration may prevent the transmission of HTLV-I, which requires cell-to-cell contact. The removal of HTLV-I-infected cells in routinely filtered blood cell components was measured. STUDY DESIGN AND METHODS: The study was conducted in Martinique where systematic screening for HTLV-I and -II and universal leukoreduction are mandatory. HTLV-I was quantified by use of real-time PCR in 8 RBC units and 4 PLT concentrates before and after filtration. HTLV-I proviral load in PBMNCs was determined in five of the eight HTLV-I-infected blood donors. RESULTS: The amount of MNC-associated HTLV-I DNA in RBC units before filtration was 21 x 10(6)+/- 29 x 10(6) copies (mean +/- SD). HTLV-I was detected in 4 of 8 RBC units after filtration, with a number of copies in the MNC fraction ranging from 20 to 140, following a 4.9 to 5.8 log reduction. Flow cytometry analysis performed in 2 of the filtered RBC units containing detectable HTLV-I showed suboptimal and out-of-range leukoreduction (0.56 x 10(6) and 1.22 x 10(6) residual WBCs). HTLV was not detected in filtered RBCs from the blood donor with the highest percentage of HTLV-I-infected PBMCs (9%). CONCLUSION: This study confirms that HTLV-I-infected cells can be detected in filtered blood cell components and shows that optimal leukoreduction is critical for HTLV-I removal.


Subject(s)
Blood Cells/virology , Blood Donors , Deltaretrovirus Infections/virology , Human T-lymphotropic virus 1/isolation & purification , Leukapheresis , Viral Load , Blood Platelets/virology , Computer Systems , DNA, Viral/analysis , Deltaretrovirus Infections/blood , Erythrocytes/virology , Filtration , Flow Cytometry , Human T-lymphotropic virus 1/genetics , Humans , Monocytes/virology , Polymerase Chain Reaction , Quality Control , Sensitivity and Specificity
14.
J Virol Methods ; 102(1-2): 37-51, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11879691

ABSTRACT

A quantitative real-time PCR assay was developed to measure the proviral load of human T-lymphotropic virus type I (HTLV-I) in peripheral blood mononuclear cells (PBMCs). The HTLV-I copy number was referred to the actual amount of cellular DNA by means of the quantitation of the albumin gene. Ten copies of HTLV-I DNA could be detected with 100% sensitivity, and the assay had a wide range of at least 5 log(10). Intra- and inter-assay reproducibility was evaluated using independent extractions of PBMCs from an HTLV-I-infected patient (coefficients of variation, 24 and 7% respectively). The performance of this TaqMan PCR assay, coupled with its high throughput, thus allows reliable routine follow-up of HTLV-I proviral load in infected patients. Preliminary results using clinical samples indicate a higher proviral load in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis than in asymptomatic carriers, and also suggest the usefulness of this quantitative measurement to assess the etiological link between HTLV-I and adult T-cell leukaemia/lymphoma-like syndromes.


Subject(s)
Leukemia-Lymphoma, Adult T-Cell/virology , Paraparesis, Tropical Spastic/virology , Polymerase Chain Reaction/methods , Proviruses/growth & development , Viral Load , Base Sequence , Carrier State , DNA, Viral , Human T-lymphotropic virus 1/genetics , Human T-lymphotropic virus 1/growth & development , Humans , Leukemia-Lymphoma, Adult T-Cell/blood , Leukocytes, Mononuclear/virology , Molecular Sequence Data , Paraparesis, Tropical Spastic/blood , Proviruses/genetics , Reproducibility of Results , Sensitivity and Specificity , Taq Polymerase
SELECTION OF CITATIONS
SEARCH DETAIL
...